Priogen is an innovative diagnostic company specializing in the ultra-sensitive detection of infectious proteins associated with prion and protein-misfolding diseases of wildlife, livestock, and humans. 

Our growing service and technology portfolio provides novel solutions aimed at the robust and rapid identification of infectious proteins, thus preventing the spread and stabilizing multiple economic sectors. Priogen's entry into the protein-diagnostic market strategically focuses on Chronic Wasting Disease (CWD), a disease of cervids (deer, elk, moose, caribou) spreading across North America, Scandinavia, and Korea.  

Our mission is to revolutionize protein diagnostic services and technologies in order to improve animal and human health, safeguard the environment and relieve protein-disease economic burdens.


Americans currently living with Alzheimer's or Parkinson's disease 

$4T (USD)

Estimated 2030 global economic losses surrounding neurodegenerative diseases  

$200B (USD)

Deer-associated economy in the U.S. at risk from CWD


In 2021 Priogen’s founding team was the first to successfully test for CWD in a field setting using our MN-QuIC™ technology, with results in less than 24 hours. We have since produced a strong, portfolio of proprietary diagnostic solutions for identifying prions in biological and environmental samples. Priogen’s scientists have designed nanotechnology-based diagnostic platforms that are portable and provide same-day results for CWD. These technologies have capabilities for human and animal prion and protein-misfolding diseases. 

Priogen's current services leverage prion amplification technology for the detection of prions in: